Novartis struck a large licensing deal with Abogen Biosciences for an mRNA-encoded autoimmune T-cell engager, with the arrangement structured around a large upfront payment and milestone-based upside. The therapy, ABO2203, targets CD19xCD3 to drive in vivo production intended to achieve B-cell depletion and an immune reset.